Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Fibronectin fragments modulate monocyte VLA-5 expression and monocyte migration
JoAnn Trial, Robert E. Baughn, James N. Wygant, Bradley W. McIntyre, Holly H. Birdsall, Keith A. Youker, Alida Evans, Mark L. Entman, Roger D. Rossen
JoAnn Trial, Robert E. Baughn, James N. Wygant, Bradley W. McIntyre, Holly H. Birdsall, Keith A. Youker, Alida Evans, Mark L. Entman, Roger D. Rossen
View: Text | PDF
Article

Fibronectin fragments modulate monocyte VLA-5 expression and monocyte migration

  • Text
  • PDF
Abstract

To identify the mechanisms that cause monocyte localization in infarcted myocardium, we studied the impact of ischemia-reperfusion injury on the surface expression and function of the monocyte fibronectin (FN) receptor VLA-5 (α5β1 integrin, CD49e/CD29). Myocardial infarction was associated with the release of FN fragments into cardiac extracellular fluids. Incubating monocytes with postreperfusion cardiac lymph that contained these FN fragments selectively reduced expression of VLA-5, an effect suppressed by specific immunoadsorption of the fragments. Treating monocytes with purified, 120-kDa cell-binding FN fragments (FN120) likewise decreased VLA-5 expression, and did so by inducing a serine proteinase–dependent proteolysis of this β1 integrin. We postulated that changes in VLA-5 expression, which were induced by interactions with cell-binding FN fragments, may alter monocyte migration into tissue FN, a prominent component of the cardiac extracellular matrix. Support for this hypothesis came from experiments showing that FN120 treatment significantly reduced both spontaneous and MCP-1–induced monocyte migration on an FN-impregnated collagen matrix. In vivo, it is likely that contact with cell-binding FN fragments also modulates VLA-5/FN adhesive interactions, and this causes monocytes to accumulate at sites where the fragment concentration is sufficient to ensure proteolytic degradation of VLA-5.

Authors

JoAnn Trial, Robert E. Baughn, James N. Wygant, Bradley W. McIntyre, Holly H. Birdsall, Keith A. Youker, Alida Evans, Mark L. Entman, Roger D. Rossen

×

Figure 5

Options: View larger image (or click on image) Download as PowerPoint
Effect of 40-kDa (FN40) and 120-kDa (FN120) fragments of FN on VLA-5 exp...
Effect of 40-kDa (FN40) and 120-kDa (FN120) fragments of FN on VLA-5 expressed by CD14+ monocytes in human blood. Graphs in a and c show the mean ± SEM for data obtained from 3 different donors. (a) Dose response. Data show mean fluorescence intensity for staining with the anti-α5 mAb clone SAM-1. Open squares represent FN40 treatment; filled squares represent FN120 treatment. Asterisks indicate data that differ significantly from untreated sample values (P < 0.05, ANOVA). The mean fluorescence intensity for an isotype-matched control mouse immunoglobulin ranged from 0.21 to 0.28 for all donors and treatments. (b) Histogram compares log immunofluorescence intensity for monocytes treated (FN120) or not treated (no Rx) with 2 μM FN120 for 2 hours before staining with mAb clone SAM-1. The solid line represents isotype-matched control mouse immunoglobulin. (c) Kinetic analysis of response to 2 μM FN120. Filled triangle represents the mean fluorescence intensity of clone SAM-1 anti-α5 on CD14+ human monocytes in whole blood. Aliquots of this blood sample were left untreated (open squares, no Rx) or treated with FN120 (filled squares, FN120). Asterisks indicate times at which results differ significantly (P < 0.05, ANOVA) from the time 0 value. Note that VLA-5 expression was significantly reduced within 5 minutes after addition of FN120. The mean fluorescence intensity for an isotype-matched control mouse immunoglobulin ranged from 0.23 to 0.29 for all donors and treatments.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts